Matinas Biopharma Holdings, Inc. (NYSE:MTNB) Short Interest Down 42.2% in July

Matinas Biopharma Holdings, Inc. (NYSE:MTNB) was the target of a large decrease in short interest in July. As of July 31st, there was short interest totaling 48,000 shares, adecreaseof42.2% from the July 15th total of 83,100 shares. Based on an average daily trading volume, of 262,100 shares, the short-interest ratio is presently 0.2 days. Approximately1.1% of the shares of the stock are sold short. Approximately1.1% of the shares of the stock are sold short. Based on an average daily trading volume, of 262,100 shares, the short-interest ratio is presently 0.2 days.

Matinas Biopharma Stock Performance

Shares of MTNB stock opened at $1.70 on Wednesday. Matinas Biopharma has a 52-week low of $0.4748 and a 52-week high of $6.55. The firm has a market capitalization of $8.65 million, a PE ratio of -0.35 and a beta of 1.32. The stock has a fifty day simple moving average of $1.05 and a two-hundred day simple moving average of $0.78.

Matinas Biopharma Company Profile

Matinas BioPharma Holdings, Inc is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D.